Experimental drug combo aims to boost pancreatic cancer treatment

NCT ID NCT06639724

Recruiting now Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding the drug fostamatinib to standard chemotherapy can help people with resectable pancreatic cancer. Fostamatinib is already approved for a blood disorder but has not been tried in pancreatic cancer. The study will enroll 36 participants to see if the combination is safe and does not delay surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fostamatinib (a Syk inhibitor) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to: If it works, this could point toward a new treatment option for resectable pancreatic cancer that may improve outcomes when added to standard chemotherapy.
What could go wrong: This is a very early phase 1b trial with only 36 participants, so it is primarily testing safety and feasibility. The drug has not been studied in pancreatic cancer before, and it may not improve outcomes or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of California, San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.